Maze Therapeutics (MAZE) slides 36.7% as investors digest fresh SEC filings ahead of a key Phase 2 catalyst

Maze Therapeutics (MAZE) is down 36.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp drop appears tied to company disclosures filed today, with investors repricing risk as Maze heads into a closely watched Phase 2 proof-of-concept readout window. While the exact market-moving line item is not obvious from headline-level information alone, clinical-stage biotech stocks can move violently when new filings update timelines, risks, or financing expectations.

Details:

Maze posted a new Form 8-K on March 25, 2026, which can act as a trigger for fast-moving re-evaluations by event-driven traders.

The company also filed its annual Form 10-K on March 25, 2026, potentially refreshing investors on cash burn, going-concern-style runway language, and risk factors typical for a pre-revenue clinical-stage biotech.

Maze’s investment narrative has been centered on its lead APOL1 program (MZE829) in the Phase 2 HORIZON study, with topline proof-of-concept data previously guided for the end of Q1 2026; with that window closing, positioning and “sell-the-news” behavior can amplify volatility.

This could also be because investors are extrapolating a higher probability of future dilution or slower development pacing after reviewing the latest disclosures (speculation).

Sources:

Maze Therapeutics (IR), U.S. SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MAZE Insider Trading Activity

$MAZE insiders have traded $MAZE stock on the open market 27 times in the past 6 months. Of those trades, 0 have been purchases and 27 have been sales.

Here’s a breakdown of recent trading of $MAZE stock by insiders over the last 6 months:

HAROLD BERNSTEIN (President, R&D & CMO) has made 0 purchases and 12 sales selling 130,156 shares for an estimated $5,776,986.
ATUL DANDEKAR (CSBO) has made 0 purchases and 6 sales selling 80,000 shares for an estimated $3,272,789.
CATHERINE A. SOHN has made 0 purchases and 2 sales selling 29,413 shares for an estimated $1,149,054.
AMY BACHRODT (SVP, Finance) has made 0 purchases and 7 sales selling 25,000 shares for an estimated $1,064,004.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MAZE Hedge Fund Activity

We have seen 98 institutional investors add shares of $MAZE stock to their portfolio, and 30 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 2,390,713 shares (+318.0%) to their portfolio in Q4 2025, for an estimated $99,047,239
TRV GP IV, LLC removed 1,600,000 shares (-26.3%) from their portfolio in Q4 2025, for an estimated $66,288,000
MATRIX CAPITAL MANAGEMENT COMPANY, LP removed 1,173,684 shares (-71.0%) from their portfolio in Q4 2025, for an estimated $48,625,728
ALPHABET INC. removed 1,023,888 shares (-42.4%) from their portfolio in Q4 2025, for an estimated $42,419,679
BLACKROCK, INC. added 971,139 shares (+73.8%) to their portfolio in Q4 2025, for an estimated $40,234,288
BELLEVUE GROUP AG added 887,708 shares (+inf%) to their portfolio in Q4 2025, for an estimated $36,777,742
CALIGAN PARTNERS LP added 550,191 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,794,413

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MAZE Analyst Ratings

Wall Street analysts have issued reports on $MAZE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 03/18/2026
Wells Fargo issued a "Overweight" rating on 12/04/2025
Wedbush issued a "Outperform" rating on 11/07/2025
JP Morgan issued a "Overweight" rating on 09/29/2025

To track analyst ratings and price targets for $MAZE, check out Quiver Quantitative's $MAZE forecast page.

$MAZE Price Targets

Multiple analysts have issued price targets for $MAZE recently. We have seen 8 analysts offer price targets for $MAZE in the last 6 months, with a median target of $58.0.

Here are some recent targets:

Danielle Brill from Truist Securities set a target price of $68.0 on 03/18/2026
Laura Chico from Wedbush set a target price of $58.0 on 03/16/2026
Salim Syed from Mizuho set a target price of $97.0 on 03/10/2026
Julian Harrison from BTIG set a target price of $46.0 on 03/09/2026
Debjit Chattopadhyay from Guggenheim set a target price of $58.0 on 03/04/2026
Sadia Rahman from Wells Fargo set a target price of $55.0 on 12/04/2025
Ananda Ghosh from HC Wainwright & Co. set a target price of $60.0 on 12/03/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.